It is not a preventive medicine. It cannot be used to stop infection before it happens.
No cruzamento entre ciência e urgência clínica, o Brasil ampliou em agosto de 2021 seu arsenal terapêutico contra a COVID-19, autorizando o uso emergencial de mais um anticorpo monoclonal — o regdanvimabe, desenvolvido pela sul-coreana Celltrion Healthcare. A aprovação pela Anvisa reconhece que a vacinação, por si só, não encerra a necessidade de tratamento: para aqueles que adoecem e carregam fatores de risco, uma janela estreita de intervenção pode ser a diferença entre recuperação e colapso. É um lembrete de que a medicina moderna avança não apenas prevenindo, mas aprendendo a interceptar o sofrimento no momento mais delicado de sua trajetória.
- Com quatro tratamentos aprovados e uma pandemia ainda em curso, o Brasil corre contra o tempo para oferecer opções reais a pacientes que adoecem apesar das vacinas.
- O regdanvimabe impõe uma tensão logística severa: a janela de sete dias a partir dos sintomas e a exigência de administração hospitalar tornam o acesso oportuno um desafio concreto.
- O medicamento não é para todos — ele foi desenhado para adultos com COVID leve a moderada que ainda não precisam de oxigênio, mas cujas condições de saúde os colocam à beira do precipício clínico.
- Evidências clínicas apontam na direção certa: redução de danos pulmonares, queda na carga viral e menor risco de hospitalização, resultados que já convenceram FDA e Agência Europeia de Medicamentos.
- A aprovação sinaliza uma maturidade regulatória — o Brasil alinha seu arsenal ao de grandes potências médicas, reconhecendo que tratar bem quem adoece é tão estratégico quanto imunizar.
Na quarta-feira, 11 de agosto de 2021, a Anvisa concedeu autorização de uso emergencial ao regdanvimabe, anticorpo monoclonal produzido pela empresa sul-coreana Celltrion Healthcare e comercializado sob o nome Regkirona. Com isso, o Brasil passou a contar com quatro tratamentos aprovados contra a COVID-19 — um reflexo da busca contínua por ferramentas que vão além da vacinação.
Anticorpos monoclonais funcionam como proteínas de laboratório que imitam as defesas naturais do organismo, identificando e neutralizando ameaças específicas. No caso do regdanvimabe, o alvo é direto: o SARS-CoV-2. Mas a Anvisa foi enfática — o medicamento não é preventivo. Ele só faz sentido depois que a infecção já se instalou, e precisa ser administrado em até sete dias após o início dos sintomas, em ambiente hospitalar, em dose única injetável.
O perfil do paciente elegível é bem definido: adultos com COVID leve a moderada, sem necessidade de oxigênio suplementar, mas com condições que aumentam o risco de agravamento — obesidade severa, diabetes, doença renal crônica, imunossupressão, idade igual ou superior a 65 anos, ou a partir de 55 anos com doenças cardiovasculares ou respiratórias crônicas. Pacientes já hospitalizados, em uso de oxigênio ou gestantes estão fora do escopo aprovado.
Os dados clínicos que embasaram a decisão mostraram redução de danos pulmonares, queda na carga viral e menor risco de hospitalização — resultados que já haviam levado FDA e a Agência Europeia de Medicamentos a aprovar anticorpos monoclonais para uso emergencial. O Brasil, ao incorporar o regdanvimabe ao lado do remdesivir, do Regn-CoV2 e da combinação bamlanivimabe-etesevimabe, consolida uma abordagem terapêutica mais robusta: para quem adoece e se enquadra nos critérios, há agora mais uma chance de evitar o pior.
Brazil's health regulator took another step forward in its COVID-19 treatment arsenal on Wednesday, August 11th, when it granted emergency authorization for regdanvimabe, a monoclonal antibody developed by South Korean pharmaceutical company Celltrion Healthcare. The drug, marketed as Regkirona, becomes the fourth such treatment approved in Brazil for combating the coronavirus, joining a growing toolkit of biological interventions designed to help the body's immune system fight back against severe infection.
Monoclonal antibodies work by mimicking the body's natural defenses—they are laboratory-produced proteins engineered to recognize and neutralize specific threats. In this case, regdanvimabe targets SARS-CoV-2 directly. But the regulatory agency was clear on one point: this is not a preventive medicine. It cannot be used to stop infection before it happens. Instead, it is meant to intervene once someone is already sick, ideally within the first week of symptoms appearing.
The practical constraints around the drug are significant. It comes as a single injectable dose, but it can only be administered in hospital settings. This requirement reflects both the nature of the treatment and the need for medical supervision during administration. Patients have a narrow window—seven days from the onset of symptoms—to receive the injection if they want to benefit from it.
Not everyone with COVID-19 qualifies for this treatment. The drug is specifically designed for adults with mild to moderate illness who are not yet requiring supplemental oxygen but face a genuine risk of deteriorating into severe disease. The regulatory approval identifies several conditions that place patients in this higher-risk category: a body mass index of 35 or greater, chronic kidney disease, diabetes, immunosuppressive conditions, age 65 and older, or age 55 and older combined with cardiovascular or chronic respiratory disease. Conversely, the drug is contraindicated for patients already hospitalized due to COVID-19, those already receiving oxygen therapy, or those who need increased oxygen flow beyond their baseline. Notably, no clinical trials were conducted in pregnant women, so the drug is not approved for use during pregnancy.
Clinical evidence supported the authorization. Researchers observed that the monoclonal antibody reduced lung damage in treated patients, lowered viral load in the bloodstream, and decreased the risk of hospitalization. These findings aligned with decisions already made by international regulators—both the U.S. Food and Drug Administration and the European Medicines Agency had previously approved monoclonal antibodies for emergency use against COVID-19.
Brazil's regulatory landscape for COVID-19 treatments has expanded considerably. Beyond regdanvimabe, Anvisa has approved remdesivir, an antiviral developed by Gilead Sciences. The agency also authorized emergency use of Regn-CoV2, a combination of two monoclonal antibodies (casirivimab and imdevimabe) developed jointly by Regeneron and Roche, as well as a pairing of banlanivimab and etesevimabe from Eli Lilly. Each represents a different approach to the same problem: giving the immune system a boost at a critical moment in the disease's progression.
The approval of regdanvimabe reflects a broader shift in how countries are managing COVID-19 beyond vaccination—recognizing that even as vaccination campaigns roll out, treatments for those who do get sick remain essential. For patients who meet the criteria and can reach a hospital within the treatment window, this new option offers another chance to avoid the worst outcomes.
Notable Quotes
Regdanvimabe is a monoclonal antibody, a biological product produced in laboratories that reproduces antibodies helping the body fight a specific disease.— Anvisa
The Hearth Conversation Another angle on the story
Why does this drug only work in the first week of symptoms? Why not later?
By day seven, the virus has already established itself deeply in the lungs and bloodstream. The antibody works best when it can intercept the virus early, before the immune system's own response becomes the main problem. After that window closes, the damage is often already done.
So it's not for the sickest patients—it's for people who are still relatively well but at risk of getting worse.
Exactly. It's a preventive intervention, but not in the sense of preventing infection. It's preventing progression. You catch someone on day three or four, before they need oxygen, and you give their immune system this targeted weapon.
Why can't it be given outside hospitals?
Monoclonal antibodies are biologics—they're complex proteins that need careful handling and monitoring. If someone has an adverse reaction, you need medical staff present immediately. It's not like a pill you can take at home.
The approval mentions people with obesity, diabetes, kidney disease. Why those specific conditions?
They all compromise the immune system's ability to fight back effectively. Someone with diabetes or kidney disease already has inflammation and reduced immune function. Age does the same thing. These patients are more likely to spiral from mild illness to critical without help.
How does this fit into Brazil's overall COVID response?
It's one tool among several now. You have vaccines for prevention, antivirals like remdesivir for early treatment, and now multiple monoclonal antibodies for high-risk patients. No single drug solves this. You need options.
Will this actually change outcomes for patients?
The clinical trials showed it reduces hospitalization risk and lung damage. For someone in that high-risk window, yes—it could mean the difference between staying home and ending up in an ICU.